目的 探討美沙拉嗪腸溶片聯(lián)合蒙脫石散治療潰瘍性結(jié)腸炎的臨床治療效果。方法 選取2017年1月-2017年12月在江蘇省濱?？h人民醫(yī)院治療的潰瘍性結(jié)腸炎患者80例作為研究對(duì)象，將患者隨機(jī)分為對(duì)照組和觀察組，每組各40例。對(duì)照組患者給予柳氮磺吡啶腸溶片，8片/次，3次/d，另給予蒙脫石散，將蒙脫石散置入50 mL的溫水內(nèi)，搖勻后服用，1次/d。觀察組患者口服美沙拉嗪腸溶片，4次/d，4片/次；聯(lián)合蒙脫石散，服用方法同對(duì)照組。所有患者均接受8周連續(xù)治療。觀察兩組患者的臨床治療效果及不良反應(yīng)發(fā)生率，并比較兩組治療前后血清樣本中腫瘤壞死因子-α（TNF-α）和白細(xì)胞介素-6（IL-6）的水平。結(jié)果 治療后，觀察組患者的臨床治療有效率為92.50%，對(duì)照組患者的臨床治療有效率為72.50%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療前，兩組患者的血清TNF-α及IL-6水平相比，差異均無統(tǒng)計(jì)學(xué)意義；治療后，兩組血清TNF-α、IL-6水平均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組患者的血清TNF-α及IL-6水平均顯著低于對(duì)照組，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組患者治療期間不良反應(yīng)發(fā)生率為12.50%，對(duì)照組患者治療期間不良反應(yīng)發(fā)生率為32.50%，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 美沙拉嗪腸溶片聯(lián)合蒙脫石散治療潰瘍性結(jié)腸炎的臨床治療效果較好，安全性較高。

Objective To investigate the clinical treatment effect of Mesalazine Enteric Coated Tablets combined with Montmorillonite Powder in treatment of ulcerative colitis. Methods Patients (80 cases) with ulcerative colitis in Jiangsu Binhai County People's Hospital from January 2017 to December 2017 were randomly divided into control group and observation group, and each group 40 cases. Patients in the control group was given Sulfasalazine Enteric-coated Tablets, 8 tablets/time, three times daily. And Montmorillonite Powder was put into 50 mL warm water, shaken and taken once a day. Patients in the observation group were given Mesalazine Enteric Coated Tablets, 4 tablets/time, four times daily, and combined with Montmorillonite Powder. Patients in two groups were treated for 8 weeks. The clinical effect and the incidence of the adverse reaction of two groups were observed, and the levels of TNF-α and IL-6 before and after treatment were compared. Results After treatment, the effective rate of clinical effect in the observation group was 92.50%, and the effective rate of clinical effect of the control group was 72.50%, the difference was statistically significant (P<0.05). Before treatment, there was no significant difference in serum TNF-α and IL-6 of the two groups. After treatment, the levels of TNF-α and IL-6 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the levels of TNF-α and IL-6 in the observation group was significantly lower than those in the control group, with significant difference between two groups (P<0.05). The adverse reaction duration of therapy of observation group was 12.50%, the incidence of the adverse reaction duration of therapy of control group was 32.50%, the difference was statistically significant (P<0.05). Conclusion Mesalazine Enteric Coated Tablets combined with Montmorillonite Powder has good effect in treatment of ulcerative colitis, and the safety is high.